Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Employees

711

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
13/03/26	56.07 $	+1.93%	265,019
12/03/26	55.01 $	-5.32%	3,770,079
11/03/26	58.10 $	-1.86%	2,894,982
10/03/26	59.20 $	-2.42%	2,174,622
09/03/26	60.67 $	+1.42%	2,260,739

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

55.01USD

Average target price

81.36USD

Spread / Average Target

+47.91%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 14:31:26 13/03/2026 GMT			5-day change	1st Jan Change
55.66 ^USD	+1.17%		-6.79%	-16.01%

02-22	Certain Warrants of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-22	Certain Options of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI

Capitalization	7.7B 6.68B 6.04B 5.77B 10.49B 711B 10.86B 71.91B 28.55B 340B 28.91B 28.29B 1,227B	P/E ratio 2026 *	-15.9x	P/E ratio 2027 *	-13.1x
Enterprise value	6.8B 5.9B 5.34B 5.1B 9.27B 628B 9.59B 63.51B 25.22B 300B 25.53B 24.99B 1,083B	EV / Sales 2026 *	15.2x	EV / Sales 2027 *	20.6x
Free-Float	94.28%	Yield 2026 *	-	Yield 2027 *	-

02-22	Certain Warrants of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-22	Certain Options of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-22	Certain Common Stock of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 - Biotechnology	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 Health Care	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from S&P 600 Health Care	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from S&P 600	CI
02-06	Arrowhead Pharmaceuticals, Inc., Q1 2026 Earnings Call, Feb 05, 2026
02-05	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M	MT
02-05	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M	MT
02-05	Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-04	Ciena Set to Join S&P500	MT

01-22	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $101 From $61, Keeps Buy Rating	MT
01-07	Chardan Adjusts Price Target on Arrowhead Pharmaceuticals to $80 From $60, Maintains Buy Rating	MT
12-11	RBC Raises Price Target on Arrowhead Pharmaceuticals to $80 From $52, Keeps Outperform, Speculative Risk	MT
11-19	RBC Raises Price Target on Arrowhead Pharmaceuticals to $52 From $45, Keeps Outperform, Speculative Risk	MT
11-12	Arrowhead Has Large Market Opportunity With Severe Hypertriglyceridemia Treatment, Morgan Stanley Says	MT

Arrowhead Pharmaceuticals, Inc. Share Price

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Valuation: Arrowhead Pharmaceuticals, Inc.

Chart: Arrowhead Pharmaceuticals, Inc.

Latest news: Arrowhead Pharmaceuticals, Inc.

Last Transcript: Arrowhead Pharmaceuticals, Inc.

Analysts' recommendations: Arrowhead Pharmaceuticals, Inc.

Press Releases: Arrowhead Pharmaceuticals, Inc.

News in other languages: Arrowhead Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Arrowhead Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

02-24	Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events	BU
02-05	Arrowhead Pharmaceuticals : ARWR FQ1 2026 Script Final	PU
02-05	Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results	BU
01-27	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia	BU
01-20	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results	BU

01-05	Arrowhead Pharmaceuticals annonce l’approbation de REDEMPLOMC (plozasiran) par Santé Canada pour réduire les triglycérides chez les adultes atteints du syndrome de chylomicronémie familiale (SCF)
02/09/25	Novartis si assicura diritti di una terapia contro Parkinson
02/09/25	Novartis s'assure les droits d'une thérapie contre Parkinson
02/09/25	Novartis sichert sich Exklusivlizenz für Parkinson-Therapie von Arrowhead
02/09/25	Novartis erhält Lizenzrechte für Parkinson-Behandlung von Arrowhead

1 day	+1.16%
1 week	-6.79%
Current month	-11.87%
1 month	-12.63%
3 months	-18.54%
6 months	+94.49%
Current year	-16.01%

1 week	54.58	60.97
1 month	54.58	67.15
Current year	54.58	76.76
1 year	9.57	76.76
3 years	9.57	76.76
5 years	9.57	93.66
10 years	1.2	93.66

Manager	Title	Age	Since
Christopher Anzalone CEO	Chief Executive Officer	56	30/11/2007
Daniel Apel DFI	Director of Finance/CFO	-	12/05/2025
Peter Carignan CTO	Chief Tech/Sci/R&D Officer	-	31/07/2022

Director	Title	Age	Since
Christopher Anzalone CHM	Chairman	56	-
Mauro Ferrari BRD	Director/Board Member	66	18/08/2010
Michael Perry BRD	Director/Board Member	66	18/12/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ARROWHEAD PHARMACEUTICALS, INC.	+1.17%	-6.79%	+270.01%	+111.05%	7.7B
ARGENX SE	+0.39%	-0.68%	+15.56%	+89.51%	43.46B
WUXI APPTEC CO., LTD.	-1.06%	-0.58%	+49.23%	+14.57%	39.86B
INSMED INCORPORATED	+0.19%	+0.24%	+87.12%	+666.76%	30.07B
BIONTECH SE	+0.92%	-11.42%	-7.75%	-30.72%	21.62B
WUXI BIOLOGICS (CAYMAN) INC.	-1.71%	-5.01%	+48.15%	-31.24%	18.57B
GENMAB A/S	-0.53%	+0.12%	+26.59%	-30.59%	16.5B
AKESO, INC.	-0.81%	+2.70%	+55.65%	+177.93%	13.08B
SUMMIT THERAPEUTICS INC.	+6.21%	+7.43%	-15.41%	+960.92%	11.99B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.75%	+2.23%	+65.88%	-	11.56B
Average	+0.65%	-1.66%	+59.50%	+214.25%	21.44B
Weighted average by Cap.	+0.24%	-1.88%	+45.74%	+184.75%

	2026 *	2027 *
Net sales	448M 388M 351M 335M 610M 41.32B 631M 4.18B 1.66B 19.74B 1.68B 1.64B 71.26B	316M 274M 248M 237M 431M 29.2B 446M 2.95B 1.17B 13.95B 1.19B 1.16B 50.36B
Net income	-494M -428M -387M -370M -673M -45.6B -696M -4.61B -1.83B -21.79B -1.85B -1.81B -78.65B	-609M -529M -478M -456M -830M -56.25B -859M -5.69B -2.26B -26.88B -2.29B -2.24B -97.01B
Net Debt	-900M -780M -706M -674M -1.23B -83.07B -1.27B -8.4B -3.33B -39.69B -3.38B -3.3B -143B	-1.18B -1.03B -927M -885M -1.61B -109B -1.67B -11.03B -4.38B -52.13B -4.43B -4.34B -188B